Abstract
Human endometrial tissue has become an attractive source of mesenchymal stem cells (MSCs) for cell-based therapies because these MSCs can be easily harvested and have tumour tropism as well as reduced immunogenic and inflammatory properties. Our study aimed to obtain and characterise human endometrial mesenchymal stem cells (EMSCs) and assess their endometriosis tropism. EMSCs were successfully isolated from the endometrium of women undergoing laparoscopy for idiopathic infertility. The EMSCs presented a fibroblast-like morphology during culture. Flow cytometry analyses showed that the cells were positive for the specific stem cell markers CD73, CD90, CD105, CD166, and HLA-ABC (major histocompatibility complex class I (MHC I)) but negative for CD14, CD34, CD45, and HLA-DR (MHC II). Reverse transcription polymerase chain reaction results showed that the EMSCs expressed the stem cell marker OCT4. The EMSCs could differentiate into osteocytes, adipocytes, and chondrocytes under certain conditions. The EMSCs had a high tropism to endometriosis without tumourigenicity. This study enhances the possibility of using EMSCs as drug carriers in human cell-based therapies. Meanwhile, future research could also focus on developing targeted therapies for endometriosis.
Highlights
Mesenchymal stem cells (MSCs) have been explored as a promising vehicle candidate for cell-based targeted therapies [1,2,3]
We propose to investigate the characteristics of endometrial mesenchymal stem cells (EMSCs) and their tropism to endometriosis, thereby laying the groundwork for targeted endometriosis therapy
EMSCs were successfully isolated through the centrifugal adherence method from endometrium tissues
Summary
Mesenchymal stem cells (MSCs) have been explored as a promising vehicle candidate for cell-based targeted therapies [1,2,3]. There have been studies on the antitumour effects of MSCs from the bone marrow and other sources [5, 8, 9], but few have focused on endometrial mesenchymal stem cells (EMSCs). EMSCs have all the characteristics of MSCs. An increasing amount of evidence suggests that EMSCs can be used for regenerative medicine and that they can be used as an immune regulator to reduce inflammation [13,14,15,16]. An increasing amount of evidence suggests that EMSCs can be used for regenerative medicine and that they can be used as an immune regulator to reduce inflammation [13,14,15,16] Their application in targeted therapies is seldom reported
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
